KNBIF
Price
$0.07
Change
-$0.01 (-12.50%)
Updated
Jan 17 closing price
Capitalization
9.55M
LQDA
Price
$12.89
Change
+$0.38 (+3.04%)
Updated
Jan 17 closing price
Capitalization
1.09B
53 days until earnings call
Ad is loading...

KNBIF vs LQDA

Header iconKNBIF vs LQDA Comparison
Open Charts KNBIF vs LQDABanner chart's image
Kane Biotech
Price$0.07
Change-$0.01 (-12.50%)
Volume$13K
Capitalization9.55M
Liquidia
Price$12.89
Change+$0.38 (+3.04%)
Volume$1.07M
Capitalization1.09B
KNBIF vs LQDA Comparison Chart
Loading...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNBIF vs. LQDA commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNBIF is a Hold and LQDA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (KNBIF: $0.07 vs. LQDA: $12.89)
Brand notoriety: KNBIF and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNBIF: 14% vs. LQDA: 131%
Market capitalization -- KNBIF: $9.55M vs. LQDA: $1.09B
KNBIF [@Biotechnology] is valued at $9.55M. LQDA’s [@Biotechnology] market capitalization is $1.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNBIF’s FA Score shows that 0 FA rating(s) are green whileLQDA’s FA Score has 1 green FA rating(s).

  • KNBIF’s FA Score: 0 green, 5 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, LQDA is a better buy in the long-term than KNBIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNBIF’s TA Score shows that 4 TA indicator(s) are bullish while LQDA’s TA Score has 5 bullish TA indicator(s).

  • KNBIF’s TA Score: 4 bullish, 2 bearish.
  • LQDA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KNBIF is a better buy in the short-term than LQDA.

Price Growth

KNBIF (@Biotechnology) experienced а -5.95% price change this week, while LQDA (@Biotechnology) price change was +5.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

LQDA is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($1.09B) has a higher market cap than KNBIF($9.55M). LQDA YTD gains are higher at: 9.609 vs. KNBIF (-5.584). KNBIF has higher annual earnings (EBITDA): -3.94M vs. LQDA (-107.21M). LQDA has more cash in the bank: 204M vs. KNBIF (544K). KNBIF has less debt than LQDA: KNBIF (2.28M) vs LQDA (2.69M). LQDA has higher revenues than KNBIF: LQDA (15.6M) vs KNBIF (2.01M).
KNBIFLQDAKNBIF / LQDA
Capitalization9.55M1.09B1%
EBITDA-3.94M-107.21M4%
Gain YTD-5.5849.609-58%
P/E Ratio1.87N/A-
Revenue2.01M15.6M13%
Total Cash544K204M0%
Total Debt2.28M2.69M85%
FUNDAMENTALS RATINGS
KNBIF vs LQDA: Fundamental Ratings
KNBIF
LQDA
OUTLOOK RATING
1..100
5045
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
10030
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
5641
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KNBIF's Valuation (40) in the null industry is in the same range as LQDA (70) in the Pharmaceuticals Major industry. This means that KNBIF’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (30) in the Pharmaceuticals Major industry is significantly better than the same rating for KNBIF (100) in the null industry. This means that LQDA’s stock grew significantly faster than KNBIF’s over the last 12 months.

LQDA's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as KNBIF (100) in the null industry. This means that LQDA’s stock grew similarly to KNBIF’s over the last 12 months.

LQDA's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as KNBIF (56) in the null industry. This means that LQDA’s stock grew similarly to KNBIF’s over the last 12 months.

KNBIF's P/E Growth Rating (65) in the null industry is somewhat better than the same rating for LQDA (100) in the Pharmaceuticals Major industry. This means that KNBIF’s stock grew somewhat faster than LQDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KNBIFLQDA
RSI
ODDS (%)
Bullish Trend 12 days ago
62%
Bearish Trend 12 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
68%
Bearish Trend 12 days ago
81%
Momentum
ODDS (%)
Bullish Trend 12 days ago
72%
Bullish Trend 12 days ago
83%
MACD
ODDS (%)
Bullish Trend 12 days ago
65%
Bullish Trend 12 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
63%
Bullish Trend 12 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
60%
Bullish Trend 12 days ago
88%
Advances
ODDS (%)
Bullish Trend 20 days ago
63%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
N/A
Bearish Trend 21 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 12 days ago
89%
Aroon
ODDS (%)
Bearish Trend 12 days ago
66%
Bullish Trend 12 days ago
88%
View a ticker or compare two or three
Ad is loading...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITEIX10.840.07
+0.65%
VY® T. Rowe Price Equity Income I
RNWGX77.800.35
+0.45%
American Funds New World R6
NDVCX16.940.07
+0.41%
MFS New Discovery Value C
BMSLX14.640.06
+0.41%
MFS Blended Research Mid Cap Eq I
PAXDX8.940.03
+0.34%
Impax Global Sustainable Infras Inv

KNBIF and

Correlation & Price change

A.I.dvisor tells us that KNBIF and CADL have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KNBIF and CADL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNBIF
1D Price
Change %
KNBIF100%
-3.07%
CADL - KNBIF
22%
Poorly correlated
-13.33%
LQDA - KNBIF
21%
Poorly correlated
+3.04%
SPHDF - KNBIF
20%
Poorly correlated
N/A
MMIRF - KNBIF
12%
Poorly correlated
N/A
IGXT - KNBIF
7%
Poorly correlated
N/A
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with ALNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+3.04%
ALNY - LQDA
37%
Loosely correlated
-1.16%
AXON - LQDA
32%
Poorly correlated
+1.37%
AVXL - LQDA
30%
Poorly correlated
-9.26%
XERS - LQDA
30%
Poorly correlated
-0.62%
KURA - LQDA
29%
Poorly correlated
+1.11%
More